Events

May 28, 2026

VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement

VERAXA Biotech has strengthened its financial position to support the closing of its business combination with Voyager Acquisition Corp. and support advancement of its pipeline of BiTAC-TCE and BiTAC-ADC programs toward clinical development and through initial value inflection points.

March 2, 2026

VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.

VERAXA's shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting. Both resolutions are prerequisites for the closing of the proposed business combination among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp.

September 30, 2025

VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology

The partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases.